Cervical cancer: Problem solved? Vaccinating girls against human papillomavirus

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 117, Issue 2, 2010, Pages 137-142

  Crosbie, E J ^a,b   Brabin, L ^b  

^a Lecturer in Gynaecological Oncology ^*  (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER SCREENING; FOLLOW UP; HUMAN; NOTE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SEX DIFFERENCE; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CONDYLOMATA ACUMINATA; DEVELOPING COUNTRIES; FEMALE; GREAT BRITAIN; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MASS SCREENING; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; PROGRAM EVALUATION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 72449152877     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2009.02369.x     Document Type: Note

References (39)

1. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008 26 (Suppl. 10 K53 61.
2. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006 118 : 2135 2145.
3. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003 9 : 37 48.
4. Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007 25 : 5399 5408.
5. Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, Kitchener H, et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008 336 : 1056 1058.
6. Department of Health. HPV vaccination programme: provisional data, as submitted by PCTs for first, second and third dose vaccine uptake for the month ending [ http://www.immunisation.nhs.uk/publications/HPV-uptake-data-April09.pdf ]. Accessed 29 June 2009.
7. Northern Ireland Executive. Health Minister announces HPV vaccine uptake figures and catch up programme [ http://www.northernireland.gov.uk/news/news- dhssps/news-dhssps-march-2009/news-dhssps-30032009-health-minister-announces. htm ]. Accessed 23 July 2009.
8. ISD Scotland. Provisional Human Papilloma Virus (HPV) Immunisation Uptake rates: as at 16 February 2009 [ http://www.isdscotland.org/isd/5922.html ]. Accessed 23 July 2009.
9. National Public Health Services for Wales. Vaccine uptake in Children in Wales, January to March 2009. Cover 90. May 2009 [ http://www.wales.nhs.uk/ sites3/Documents/457/Cover%202009%20quarter1%20%28COVER90%29.pdf ]. Accessed 23 July 2009.
10. Colucci R, Hryniuk W, Savage C. HPV vaccination programs in Canada. Report Card on Cancer in Canada. 2008 [ http://www.canceradvocacy.ca/reportcard/ 2008/reportcard-2008.pdf ]. Accessed 23 July 2009.
11. European Cervical Cancer Association. HPV Vaccination Across Europe. Belgium : ECCA, 2009.
12. Kmietowicz Z. Opportunity was missed in choice of cervical cancer vaccine, health campaigners say. BMJ 2008 336 : 1456 1457.
13. Haug CJ. Human papillomavirus vaccination - reasons for caution. N Engl J Med 2008 359 : 861 862.
14. Kubba T. Human papillomavirus vaccination in the United Kingdom: what about boys? Reprod Health Matters 2008 16 : 97 103.
15. Stretch R, Roberts SA, McCann R, Baxter D, Chambers G, Kitchener H, et al. Parental attitudes and information needs in an adolescent HPV vaccination programme. Br J Cancer 2008 99 : 1908 1911.
16. O'Mahony C. (Not) warts and all. "Annoyance" of genital warts. BMJ 2008 337 : a2553.
17. Hull SC, Caplan AL. Genital warts: mountains or molehills? Lancet Infect Dis 2008 8 : 277 278.
18. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008 337 : a769.
19. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009 5 : [Epub ahead of print].
20. Schwartz JL, Caplan AL, Faden RR, Sugarman J. Lessons from the failure of human papillomavirus vaccine state requirements. Clin Pharmacol Ther 2007 82 : 760 763.
21. Bottiger M, Forsgren M. Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination. Vaccine 1997 15 : 1538 1544.
22. Vyse AJ, Gay NJ, White JM, Ramsay ME, Brown DW, Cohen BJ, et al. Evolution of surveillance of measles, mumps, and rubella in England and Wales: providing the platform for evidence-based vaccination policy. Epidemiol Rev 2002 24 : 125 136.
23. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006 24 (Suppl. 3 S3/178 86.
24. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 2008 26 (Suppl. 10 K76 86.
25. Nielsen A, Munk C, Liaw KL, Kjaer SK. Awareness of human papillomavirus in 23 000 Danish men from the general male population. Eur J Cancer Prev 2009 18 : 236 239.
26. Johnson AM, Mercer CH, Erens B, Copas AJ, McManus S, Wellings K, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001 358 : 1835 1842.
27. Gerend MA, Barley J. Human papillomavirus vaccine acceptability among young adult men. Sex Transm Dis 2009 36 : 58 62.
28. Roberts M. Gay men seek "female cancer" jab. 2007 [ http://www.news.bbc.co.uk/1/hi/health/6342105.stm ]. Accessed 16 June 2009.
29. World Health Organisation. Human Papillomavirus and HPV Vaccines. Technical Information for Policy Makers and Health Professionals. WHO/IVB/07.05. Geneva : WHO Press, 2007.
30. Baden LR, Curfman GD, Morrissey S, Drazen JM. Human papillomavirus vaccine - opportunity and challenge. N Engl J Med 2007 356 : 1990 1991.
31. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009 101 : 475 487.
32. Crosbie EJ, Kitchener HC. Human papillomavirus in cervical screening and vaccination. Clin Sci (Lond). 2006 110 : 543 552.
33. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008 179 : 525 533.
34. Daily Mail. How safe is the cervical cancer jab? Five teenagers reveal their alarming stories [ http://www.dailymail.co.uk/health/article-1167803/How- safe-cervical-cancer-jab-Five-teenagers-reveal-alarming-stories.html ] Accessed 6 April 2009.
35. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007 356 : 1915 1927.
36. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007 356 : 1928 1943. (Pubitemid 46740303)
37. Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, Kitchener H, et al. Uptake of the third dose of human papillomavirus vaccine by adolescent schoolgirls: the Manchester study. BMJ [Rapid Responses]. 2008 336 : 1056 1058. Post script appended 5 Dec 2008.
38. Middleman AB, Kozinetz CA, Robertson LM, DuRant RH, Emans SJ. The effect of late doses on the achievement of seroprotection and antibody titer levels with hepatitis B immunization among adolescents. Pediatrics 2001 107 : 1065 1069.
39. Stretch R. Implementing a school-based HPV vaccination programme. Nurs Times 2008 104 : 30 3.